Holen Sie sich die Stockscreener-App
5.60
4.11%
-0.24
Handel nachbörslich:
5.59
-0.010
-0.18%
Verastem Inc Aktie (VSTM) Neueste Nachrichten
Verastem (VSTM) Q4 2025 Earnings Call Transcript - AOL.com
Verastem's (VSTM) Buy Rating Reaffirmed at BTIG Research - MarketBeat
Verastem stock initiated at Buy by BTIG with $19 price target - Investing.com
Wall Street Analysts See a 159.31% Upside in Verastem (VSTM): Can the Stock Really Move This High? - Yahoo Finance
Jefferies Financial Group Inc. Increases Stake in Verastem, Inc. $VSTM - MarketBeat
Earnings call transcript: Verastem’s Q4 2025 results highlight oncology growth - Investing.com Nigeria
Verastem Earnings Call: Early Momentum, Long Runway Risks - TipRanks
Verastem (NASDAQ:VSTM) Raised to Hold at Wall Street Zen - MarketBeat
Verastem, Inc. (NASDAQ:VSTM) Q4 2025 Earnings Call Transcript - Insider Monkey
Jefferies Maintains Buy on Verastem, Inc. (VSTM) March 2026 - Meyka
Verastem (VSTM) Q4 Revenue Debut Highlights Ongoing Losses And Tests Bullish Profitability Timeline - simplywall.st
Verastem 2025 Financial Results: Q4 and Annual Revenue & LossNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Why Did Verastem Stock Jump After-Hours Despite An Earnings Miss? - Stocktwits
Jefferies reiterates Verastem stock rating on launch progress By Investing.com - Investing.com Canada
Verastem, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Verastem, Inc. (NASDAQ:VSTM) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Verastem Inc (VSTM) Q4 2025 Earnings Call Highlights: Transition to Commercial Stage and Financial Challenges - GuruFocus
Verastem Q4 2025 Earnings Call Transcript - MarketBeat
Verastem Q4 Earnings Call Highlights - MarketBeat
Verastem: Fourth Quarter Financial Results Overview - Bitget
Verastem (VSTM) Reports Strong Q4 2025 Earnings and Progress in Clinical Trials - GuruFocus
Key Developments for Verastem (VSTM) in 2026 Clinical Trials - GuruFocus
Verastem Highlights AVMAPKI FAKZYNJA Strategy and Pipeline Risks - TipRanks
Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Verastem (VSTM) Reports Strong Revenue and Advances Cancer Treat - GuruFocus
Verastem (NASDAQ:VSTM) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Verastem: Q4 Earnings Snapshot - KVUE
Verastem, Inc. releases Q4 and year end 2025 results with business update - Traders Union
Verastem (VSTM) shares updated March 4, 2026 corporate presentation - Stock Titan
Earnings Summary: Verastem Q4 - Benzinga
Verastem (NASDAQ: VSTM) grows LGSOC launch and advances KRAS G12D programs - Stock Titan
Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates - Business Wire
Earnings Outlook For Verastem - Benzinga
VSTM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Verastem (VSTM): Can This Beaten-Down Biotech Still Surprise Wall Street? - AD HOC NEWS
Will Avmapki Fakzynja Co-Pack Drive Sustainable Growth For Verastem This Year? - RTTNews
Verastem (VSTM) Projected to Post Earnings on Wednesday - MarketBeat
VSTM Technical Analysis & ETF Price Forecast - Intellectia AI
Balyasny Asset Management L.P. Increases Stake in Verastem Inc. - GuruFocus
Verastem, Inc. (VSTM) Stock Analysis: Navigating the 179% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - Business Wire
What Makes Verastem (VSTM) a New Buy Stock - Yahoo Finance
RTW holds 7.84M Verastem (VSTM) shares with ownership capped at 9.99% - Stock Titan
Verastem Touts 50%+ Sales Growth for LGSOC Launch, Teases RAMP 301 and KRAS G12D Catalysts - MarketBeat
Verastem, Inc. (VSTM) Investor Outlook: Unveiling A Potential 184.67% Upside In Biotech - DirectorsTalk Interviews
Gap Down: What analysts say about Verastem Inc stock2025 Historical Comparison & Stock Timing and Entry Methods - baoquankhu1.vn
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):